Abstract:e21173 Background: Anlotinib is a novel oral small molecule TKI with anti-tumor vascular generation and growth inhibition effects, targeting VEGFR, PDGFR, FGFR, and c-kit. It has been shown to be highly effective and low toxicity in the ALTER 0303 study and was approved by NMPA in 2018 for the treatment of NSCLC(non-small cell lung cancer)as third-line and above. Previous studies have shown that anlotinib can benefit patients with advanced NSCLC, especially those in the front-line(first-/second-line). This real-world study aims to update the efficacy of anlotinib in treating NSCLC and to screen the advantage population for anlotinib treatment from front-line/back-line (third-/above-line) treatment, pathological subtype, metastasis site, gene mutation, to provide more effective anlotinib treatment strategies. Methods: This is a multicenter, retrospective, real-world study. Patients with NSCLC who have received anlotinib are included, and subgroup analysis is performed based on pathological subtypes, clinical stages, gene mutations (EGFR mutant/wildtype), front-line/back-line treatments, exploring the impact of different factors on the PFS and OS of NSCLC patients using anlotinib. Results: As of September 2022, a total of 478 patients diagnosed with NSCLC were enrolled in the study, of which 434 were evaluable, with a median age of 63 years, 263 (60.6%) were male, adenocarcinoma in 292 (67.3%), squamous cell carcinoma in 75 (17.3%). At baseline, 59 patients (13.6%) had brain metastasis, 39 (9.0%) had liver metastasis, 127 (29.3%) had bone metastasis, 194 cases (44.7%) had genetic mutations, including 135 cases (31.1%) carrying EGFR mutations. 198 patients (45.6%) received anlotinib as front-line treatment, and 236 patients (54.4%) as back-line treatment. The median follow-up time was 5.09 months (95% Cl, 2.86-7.16), with a mPFS of 4.37 months (95% Cl: 3.78-5.45) in the overall population and a mOS of 20.34 months (95% Cl: 14.88-NA). Among the 138 patients who were evaluable for efficacy, 0 cases achieved complete response (CR), 6 cases partial response (PR), and 57 cases stable disease (SD). ORR was 4.3%, and DCR was 44.9%. The mPFS of front-line was longer than the back-line (5.45 vs 3.52 months), and front-line group had a longer mOS than back-line (NR vs 16.03 months). Subgroup analysis did not find any correlations between pathological subtype or EGFR mutations and patient PFS and OS. However, it was found that the presence of liver and bone metastasis at baseline was related to a shorter OS with anlotinib in the back-line (8.28 vs 16.23 months, p = 0.0253; 7.89 months vs NR, p < 0.001). Conclusions: Anlotinib shows well efficacy in NSCLC patients, prolonging progression-free survival (PFS) and overall survival (OS), especially for front-line patients, suggesting that these patients may be a preferred population for using anlotinib, providing effective evidence for the use of anlotinib treatment for NSCLC patients.

Efficiency Of Anlotinib Hydrochloride As 3rd Line Treatment In Patients (Pts) From A Randomized, Double-Blind, Placebo-Controlled Phase Iii Trial, An Exploratory Subgroup Analysis Of Alter0303 Trial For The Previous Therapy Strategy Effect

Third-line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study—efficacy and Safety of Anlotinib Treatment in Patients with Refractory Advanced NSCLC.

The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial

Subgroup Analysis of Histology in ALTER0303: Anlotinib Hydrochloride As 3rd Line and Further Line Treatment in Refractory Advanced NSCLC Patients (Pts).

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

P3.01-087 Impact Factor Analysis for Efficacy and Prognosis of Anlotinib in NSCLC As Third-Line Treatment: Data from Trial ALTER 0303

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)

Association Between Anlotinib Trough Plasma Concentration and Treatment Outcomes in Advanced Non-Small-cell Lung Cancer

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Effect of Anlotinib in Advanced Small Cell Lung Cancer (SCLC) Patients Relapsed Within Three Months after Second-Line Treatment: A Subgroup Analysis from a Randomized, Double-Blind Phase II Trial (ALTER 1202).

Effect of Prior Thoracic Radiotherapy on Prognosis in Relapsed Small Cell Lung Cancer Patients Treated with Anlotinib: a Subgroup Analysis of the ALTER 1202 Trial.

Anlotinib As Third-or Further-Line Therapy for Short-Term Relapsed Small-Cell Lung Cancer:Subgroup Analysis of a Randomized Phase 2 Study(alter1202)

A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018.

Dose Modification and Therapy Interruption Due to Adverse Events in Treatment with Anlotinib for Refractory Advanced NSCLC: Data from ALTER0303

Third‐line or above Anlotinib in Relapsed and Refractory Small Cell Lung Cancer Patients with Brain Metastases: A Post Hoc Analysis of ALTER1202, a Randomized, Double‐blind Phase 2 Study

Update on real-world efficacy of anlotinib in non-small cell lung cancer.

1036P Anlotinib Plus Docetaxel Vs. Docetaxel As 2Nd-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from ALTER-L016

The Efficacy Of Anlotinib In Squamous Cell Carcinoma (Scc) Patients With Or Without Hypertension In Alter0303: Anlotinib As A Third-Line Therapy In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc).

A Modified Phase 1 Clinical Trial of Abivertinib (ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

P48.01 Anlotinib Plus Docetaxel Vs Docetaxel for 2Nd-Line Treatment of EGFR Negative NSCLC (ALTER-L018): A Randomized Phase II Trial

A Randomized Phase Ii Trial Of Anlotinib Plus Docetaxel Vs Docetaxel For Second-Line Treatment Of Egfr-Negative Nsclc (Alter-L018)